Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma
|
|
- Annabel York
- 6 years ago
- Views:
Transcription
1 Clinical Chemistry 56: (2010) Clinical Case Study Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma Kazunori Murata, 1 Raynell J. Clark, 1 Karen S. Lockington, 1 Linda J. Tostrud, 1 Philip R. Greipp, 2 and Jerry A. Katzmann 1,2* CASE A 53-year-old woman presented to the orthopedic department with severe diffuse muscular and bone pain. An x-ray of her right upper extremity revealed a lytic destructive lesion in the right humerus. Computed tomography scans showed multiple lytic lesions in the spine and pelvis, and a biopsy confirmed the presence of 70% plasma cells, which were light chain restricted. The patient was referred to a hematologist. Although no monoclonal protein was detected in the serum by protein electrophoresis or by immunofixation electrophoresis (IFE), 3 the free light chain (FLC) was increased at 47.2 mg/l (reference interval, mg/l), with a / FLC ratio of 23 (reference interval, ). Serum concentrations of 2 - microglobulin and albumin were 248 nmol/l (reference interval, nmol/l) and 37 g/l (reference interval, g/l), respectively. The urine protein concentration was not increased, but protein electrophoresis revealed a small M (monoclonal) spike in the region (32 mg/24 h). In addition, IFE identified a monoclonal light chain (Bence Jones protein). On the basis of these findings, the patient was informed that she had stage I (International Staging System) oligosecretory/nonsecretory multiple myeloma (MM). The patient underwent surgical repair of her right humerus and was evaluated 1 month after her surgery. At that point, a second serum FLC measurement showed a FLC concentration of 68.2 mg/l. The patient s hematologist recommended close observation in lieu of initiating therapy because of her lack of symptoms. The patient s serum FLC concentration was monitored monthly and remained 50 mg/l for the next 3 months. Five months after diagnosis, the patient began to complain of mild fatigue, shortness of breath, and palpitations. A 10-fold increase in the urinary M QUESTIONS TO CONSIDER 1. Why was the patient s high serum FLC initially not detected by IFE? 2. What are the potential causes of increased FLC after treatment? 3. How can light-chain escape be differentiated from FLC antigen excess? protein to 333 mg/24 h was noted, along with a decrease in the blood hemoglobin concentration to 79 g/l (reference interval, g/l) and an increase in the calcium concentration to 2.80 mmol/l (reference interval, mmol/l). Her hematologist recommended initiation of treatment, and the patient was enrolled in a clinical trial protocol consisting of lenalidomide (25 mg/day) and dexamethasone (40 mg/ day) administered for 21 days of a 28-day cycle. At 1 month after initiation of treatment, the patient was noted to be tolerating the regimen well, with an increase in her hemoglobin to 91 g/l, a minimal decrease in serum IgG from a pretreatment value of 2.95 g/l to 2.71 g/l (reference interval, g/l), and a reduction in her serum creatinine concentration from 115 mol/l to 88 mol/l (reference interval, mol/l). The patient also stated that she felt less fatigued. Her serum FLC concentration, however, was inexplicably increased to 2180 mg/l (Fig. 1). By her next follow-up appointment a month later, the patient had completed 2 full cycles of the lenalidomide and dexamethasone regimen and showed evidence of continued response, as evidenced by a rise in the hemoglobin concentration to 105 g/l and a decrease in urinary protein excretion to 132 mg/24 h. The patient s serum FLC concentration remained increased at 1500 mg/l, however. DISCUSSION 1 Department of Laboratory Medicine and Pathology and 2 Division of Hematology, Mayo Clinic, Rochester, MN, MO. * Address correspondence to this author at: Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st St. SW, Rochester, MN katzmann@mayo.edu. Received June 30, 2009; accepted October 1, DOI: /clinchem Nonstandard abbreviations: IFE, immunofixation electrophoresis; FLC, free light chain; MM, multiple myeloma; LEPP, light-chain escape from plateau phase. MM, a hematologic malignancy belonging to a class of diseases known as plasma cell proliferative disorders, is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. The clone proliferates in the bone marrow and often produces osteolytic bone lesions, osteopenia, osteoporosis, and/or pathologic fractures. The mono- 16
2 Serum FLC (mg/l) chemotherapy initiated day 152 Despite its utility, the FLC assay is not without its limitations. Lot-to-lot variation in assay reagents can be an issue. In addition, both polyclonal and monoclonal serum FLCs have often been found to dilute in a nonlinear fashion, leading to underestimation in the absence of off-line dilution (3). False high results may occur due to polymerization of light chains (4, 5). Finally, falsely low serum FLC results may be obtained in cases of antigen excess (6) Days Fig. 1. Serum FLC concentrations reported for the patient over time. A noteworthy spike occurred immediately after initiation of treatment with lenalidomide/dexamethasone. clonal proteins may cause further organ damage, often leading to renal insufficiency and/or renal failure. The median age of diagnosis for MM is 66 years; only 2% of patients are younger than 40 years (1). MM patients often present with bone pain. Weakness and fatigue are also a common manifestation of MM and are often associated with anemia. Radiographic imaging of the skeleton reveals punched-out lytic lesions, diffuse osteopenia, osteoporosis, or fractures in nearly 80% of patients. Computed tomography and magnetic resonance imaging may be helpful for patients presenting with no abnormalities apparent on conventional x-rays. Examination of the bone marrow reveals bone marrow involvement by plasma cells, which constitute 10% of all nucleated cells in 96% of MM patients; this finding is confirmatory for MM. Laboratory findings at the time of diagnosis include anemia (73% of patients), increased serum creatinine (50%), hypercalcemia (28%), and leukopenia (20%). Serum 2 - microglobulin may also be increased (75%) and serves as a prognostic indicator, with higher values predicting poorer survival prospects. M protein is detected by IFE in the serum and/or urine in 97% of patients (1). QUANTIFICATION OF M PROTEINS IN THE DIAGNOSIS AND MANAGEMENT OF MM The serum FLC assay was developed in the early 2000s to detect light-chain epitopes that are exposed only when not bound to a heavy chain. The assay quantifies and FLCs and has come into routine use in the diagnosis and management of several plasma cell proliferative disorders, including monoclonal gammopathy of undetermined significance, light-chain amyloidosis, and MM. The clinical utility of the FLC assay has been reviewed elsewhere (2). WHAT CAUSED THE INCREASE IN SERUM FLC AFTER TREATMENT IN THIS PATIENT? For our patient, the hematologist sought the consultation of the laboratory director after consecutive monthly measurements of the serum free chain produced values much higher than before the initiation of treatment. The sudden increase in serum FLC after treatment was worrisome to the hematologist because it may have been indicative of a phenomenon referred to as light-chain escape from plateau phase (LEPP) (7). LEPP was documented in a series of 3 MM patients who were noted to undergo a shift in secretion from intact immunoglobulin to FLCs after treatment with either thalidomide or lenalidomide. LEPP is thought to be a novel manifestation of relapsed disease due to selective pressure brought on by thalidomide/lenalidomide treatment. It typically follows an aggressive clinical course, with subsequent therapies offering only marginal benefits. Fortunately, the sample from the patient s second pretreatment visit had been stored frozen. Retesting of this sample at a starting dilution of 1 part in 400 (i.e., 400-fold dilution) instead of 1 part in 100 (100-fold dilution) indicated the need for further sample dilutions and yielded a final FLC concentration of mg/l instead of the initially reported 68.2 mg/l. Nephelometric assays measure light scatter caused by the formation of immune complexes in solution and are subject to limitations inherent in antigen antibody reactions. This method requires that antigen concentrations fall within a certain range known as the antibody excess of the Heidelberger Kendall curve. Higher antigen concentrations produce falsely low readings. In this particular case, the patient had extremely high FLC concentrations that caused antigen excess and an artifactually low reading before treatment. Treatment with dexamethasone and lenalidomide caused a drop in this patient s FLC value to within the region of equivalence for the assay, causing what was perceived to be a spurious increase in concentration. WHAT IS THE PREVALENCE OF ANTIGEN EXCESS IN THE FLC ASSAY? After this case, our laboratory identified an additional 4 MM patients (2 cases of light-chain MM, 1 of nonse- Clinical Chemistry 56:1 (2010) 17
3 cretory MM, and 1 of IgA MM) who had artifactually low serum FLC concentrations during the course of disease monitoring. This experience prompted us to further investigate the incidence of serum FLC antigen excess. During a 4-month period (August 1, 2006, to November 30, 2006), all clinical FLC assays ordered in our laboratory were performed at the recommended 100-fold dilution as well as at a second (400-fold) dilution (8). FLC assays were performed on a Dade Behring BN II nephelometer with FLC reagent sets from The Binding Site (Birmingham, UK). Of the 7538 serum FLC studies that were clinically ordered and assayed in duplicate during this period, no samples exhibited FLC antigen excess, but 9 patients (0.12%) were identified to have FLC excess. These 9 patients all had increased FLC concentrations and abnormal / FLC ratios when tested at the initial 100-fold dilution, but the instrument did not indicate a need for further dilutions. When retested at a 400-fold dilution, however, all 9 samples gave substantially higher results or indicated that additional dilutions were needed. Four of the 9 patients had 2 samples submitted for testing, and each pair of samples yielded similar results. The sample with the largest change in the FLC result was from 77 mg/l to mg/l. On average, the concentrations of these samples increased approximately 200-fold when they were diluted. Diagnostically, the assay identified all 9 samples as abnormal. From a monitoring standpoint, however, the initial FLC results were misleadingly lower than the results obtained at a higher starting dilution. Some nephelometers, including the BN II, have automated detection algorithms designed to detect antigen excess. Such algorithms may include monitoring the initial rate of the precipitin reaction as well as a separate prereaction step. The manufacturer s protocol for the Freelite assay does not include a prereaction step and relies on whether the result lies beyond the linear portion of the calibration curve, as well as on the initial rate of precipitin formation, to determine if further dilutions are necessary. This protocol may have led to the analyzer missing certain cases of antigen excess. Because of these findings, we have modified the laboratory operating procedure. All sera with a FLC / ratio 2 and a FLC concentration that has not been obtained at test dilutions 100-fold are retested at a serum dilution of 400-fold. In samples that are not in antigen excess, the 400-fold dilutions give concentrations that are 50% higher on average than those obtained with the 100-fold dilutions. For consistency, the 100-fold dilutions are reported. Our choice of the 100- fold dilution for reporting purposes is based on the fact that most samples have the 100-fold dilution within the linear portion of the calibration curve. POINTS TO REMEMBER 1. Serum FLC is a sensitive test for the diagnosis of monoclonal FLC disease. 2. Increases in the FLC concentration after treatment for MM may be due to a light-chain escape phenomenon, referred to as light-chain escape from plateau phase (LEPP). 3. Our practice has a high percentage (55%) of abnormal FLC ratios in submitted samples, and approximately 0.1% of the sera in our practice are in FLC excess. No cases of FLC excess have been observed. 4. Because of the potential for FLC antigen excess, newly identified cases with abnormally high ratios should be retested with a further dilution. declared any potential conflicts of interest. Acknowledgments: FLC reagent sets for the dilution studies were provided at no charge by The Binding Site Ltd. 1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78: Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23: Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007;376: Abraham RS, Charlesworth MC, Owen BA, Benson LM, Katzmann JA, Reeder CB, Kyle RA. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin Chem 2002;48: Emond JP, Harding S, Lemieux B. Aggregation of serum free light chains (FLC) causes overestimation of FLC nephelometric results as compared to serum protein electrophoresis (SPE) while preserving clinical usefulness [Abstract]. Blood 2007;110:265. Abstract Daval S, Tridon A, Mazeron N, Ristori JM, Evrard B. Risk of antigen excess in serum free light chain measurements. Clin Chem 2007;53: Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007;92: Clark RJ, Lockington KS, Tostrud LJ, Katzmann JA. Incidence of antigen excess in serum free light chain assays [Abstract]. Clin Chem 2007;53(S6):A Clinical Chemistry 56:1 (2010)
4 Commentary Jim D. Faix Quantitative measurement of serum free light chain is an important part of the diagnosis and management of multiple myeloma and related disorders. Recent consensus guidelines (1) focus on screening for the presence of monoclonal immunoglobulin and monitoring treatment in patients with amyloidosis or oligosecretory disease. As we expand our use of this assay to monitoring patients with intact monoclonal immunoglobulin, it is clear that some technical limitations still need to be resolved. This clinical case study reminds us that one of the original drawbacks of nephelometric determinations antigen excess may be important when measuring serum free light chain. Antigen excess is due to inhibition of immune complex formation in the presence of very high antigen concentrations (2). Although manufacturers have largely eliminated this problem in noncompetitive immunoassays by either the use of sequential incubations or increasing the amount of solid-phase antibody, these approaches are not feasible for nephelometric assays. Consequently, unless the instrument s software is able to detect possible antigen excess, the laboratory must rule it out by repeating the analysis with a higher dilution. If antigen excess is present, the final result will be higher, paradoxically, because the inhibition of immune complex formation has been removed. Although this problem has been described before with the serum free light chain assay, the authors of the case study provide important context by documenting its relatively low prevalence. This fact might indicate that it is not necessary to routinely test serum samples for free light chain at more than the initial dilution. As in all areas of laboratory medicine, however, no individual result should be interpreted without consideration of other results, as well as the clinical picture. decalred any potential conflicts of interest. Stanford University School of Medicine, Department of Pathology, Stanford, CA. Address correspondence to the author at: Stanford University, Department of Pathology, 300 Pasteur Dr., Rm. H1507, Stanford, CA jim.faix@stanford.edu. Received September 8, 2009; accepted September 25, Previously published online at DOI: /clinchem Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23: Hortin GL, Remaley AT. Introduction to protein analysis. In: Detrick B, Hamilton RG, Folds JD, eds. Manual of molecular and clinical laboratory immunology. 7th ed. Washington, DC: ASM Press; Commentary Morey A. Blinder Departments of Internal Medicine and Pathology & Immunology, Washington University School of Medicine, St. Louis, MO. Address correspondence to the author at: Departments of Internal Medicine and Pathology & Immunology, Washington University School of Medicine, 660 S. Euclid Ave. Box 8125, St. Louis, MO Fax ; mblinder@ dom.wustl.edu. Received November 6, 2009; accepted November 6, DOI: /clinchem In the mid-19th century, Henry Bence Jones described the presence of free light chains (FLCs) in urine (1).A century later, work by Korngold and Lipari (2) characterized Bence Jones proteins and showed that they reacted with those found in myeloma. Although rarely appreciated, the designation of and for the 2 forms of Bence Jones proteins has remained standard nomenclature in tribute to those investigators. Nearly another half-century passed before immunoassays were developed to identify serum FLCs and begin to define their role (3). Coincident with the development of serum FLC assays have been major improvements in the treatment of myeloma. Patients now have therapeutic options that include combinations of corticosteroids, thalidomide, lenalidomide, bortezomib, and stem cell transplant, along with newer investigational agents; thus, Clinical Chemistry 56:1 (2010) 19
5 the prognosis for patients with myeloma continues to improve. The consequence of heightened awareness, a cavalcade of therapy, and prolonged survival have led to increased laboratory monitoring, reflected in the explosion of investigations using serum FLCs. Yet, as with many such advances, cautionary tales arise. In the case presented here, a patient with myeloma was followed for 4 months without symptoms, and apparently comforted by the presence of a low concentration of serum FLCs. As her disease burden worsened, traditional laboratory test results, including hemoglobin, serum calcium, and urinary M-protein, indicated advancing myeloma, and treatment was begun. Although the patient improved, the serum FLCs markedly increased. This contradiction was resolved when previously stored samples were retested at a higher dilution, indicating that large antigen excess led to an artificially low result. The authors noted that this occurred in approximately 0.1% of samples, although it would be difficult to predict who might be at risk for this finding and whether earlier identification would have ultimately changed the outcome. As highlighted in this case, discordant results need to be further investigated, and there is no substitution for careful clinical observation. declared any potential conflicts of interest. 1. Jones HB. Papers on chem pathology. Lecture III. Lancet 1847;50: Korngold L, Lipari R. Multiple-myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gamma-globulin and multiple-myeloma serum proteins. Cancer 1956;9: Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47: Clinical Chemistry 56:1 (2010)
Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies
Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies Montgomery Lobe, MD, and Donald Pasquale, MD Abstract Monoclonal gammopathies are characterized by production of monoclonal
More informationWhat do you do, with an M protein?
What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily
More informationUrine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples
Immunopathology / Electrophoresis of Unconcentrated Urine Samples Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples Anja C. Roden, MD,
More informationAssessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs Population
Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol 36, no. 2, 2006 157 Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs
More informationDiagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationSerum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma
Serum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma Kelly Endean PhD Scientific Affairs Manager, The Binding Site Focus of this talk An introduction to heavy-light chain
More informationElevated Immunoglobulins and Paraproteins
Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,
More informationDiagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
Hutchison et al. BMC Clinical Pathology 2012, 12:12 TECHNICAL ADVANCE Open Access Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
More informationSerum Free Light Chain Assays
Freelite Serum Free Light Chain Assays An aid to the diagnosis of: Light Chain (Bence Jones) Multiple Myeloma (LCMM) Nonsecretory Multiple Myeloma (NSMM) AL amyloidosis Light Chain Deposition Disease (LCDD)
More informationMeasuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014
Measuring Myeloma in the LAB BL Ferry Clinical Lead Sept 15 th 2014 Oxford Immunology Laboratory Clinical Immunology Churchill WHAT DO WE MEASURE AND HOW? Clinical Immunology Churchill Serum proteins Proteins
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Hans Lee, MD Assistant Professor Department of Lymphoma/Myeloma University of Texas MD Anderson Cancer Center No Disclosures
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016
MYELOMA FORMS The guidelines and figures below are specific to Myeloma studies. The information in this manual does NOT represent a complete set of required forms for any myeloma study. Please refer to
More informationMultiple Myeloma Patient Handbook
Myeloma Canada Mailing Address: Myeloma Canada 1255 Trans-Canada Highway Suite 160 Dorval, QC H9P 2V4 Telephone: Toll-free: 1-888-798-5771 E-mail: contact@myeloma.ca Multiple Myeloma Patient Handbook Website:
More informationCASE REPORT AND REVIEW OF THE LITERATURE
Page 76 / SA ORTHOPAEDIC JOURNAL Summer 2009 C ASE R EPORT AND R EVIEW OF THE L ITERATURE Low-secretory multiple myeloma HF Visser MBChB(Pret) Senior Registrar, Department Orthopaedic Surgery, University
More informationAssessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin / Ratios
Clinical Chemistry 55:9 1646 1655 (2009) Cancer Diagnostics Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin / Ratios Arthur R. Bradwell, 1,2* Stephen J.
More informationMultiple myeloma (MM) & related disorders
Multiple myeloma (MM) & related disorders Plasma cell neoplasms Six major variants: (1) Multiple myeloma (2) Solitary plasmacytoma (3) Lymphoplasmacytic lymphoma They secrete a single complete or partial
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus
More informationManaging Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know
Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended
More informationSmouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:
Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.
More informationUnderstanding MGUS and Smoldering Multiple Myeloma
Multiple Myeloma Cancer of the Bone Marrow Understanding MGUS and Smoldering Multiple Myeloma u-mgus+smm_en_2017_i1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE
More informationLaboratories and the New IMWG Myeloma Guidelines
Laboratories and the New IMWG Myeloma Guidelines David F. Keren, M.D. Professor of Pathology Division Director, Clinical Pathology The University of Michigan dkeren@med.umich.edu Speaker Disclosure In
More informationThis Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed.
MGUS This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed. What is MGUS? Monoclonal gammopathy of undetermined significance, or
More informationNephelometry and turbidimetry are liquid based immunoassays based on the measurement of scattered or absorbed light.
1 Nephelometry and turbidimetry are liquid based immunoassays based on the measurement of scattered or absorbed light. Light scattering is the physical phenomenon resulting from the interaction of light
More informationSerum Free Light Chain Analysis
Serum Free Light Chain Analysis Rajeevan Selvaratnam, Jing Cao and Amy B. Karger Introduction In healthy individuals, plasma cells originating from the bone marrow produce immunoglobulin molecules composed
More informationAnalytically coherent
ZO M OCTOBER 2017 N 7 sebia FLC Free light chain testing coherent with electrophoretic methods Analytically coherent SPE: 3.1 g/l FLC Nephelometry: 32.2 g/l FLC ELISA: 3.1 g/l Principle The sebia FLC Kappa
More informationManagement of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison
Management of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison Consultant Nephrologist, Hawke s Bay DHB, NZ Senior Lecturer, University of Birmingham, Birmingham, UK Why are nephrologists interested
More informationClinico hematological profile of multiple myeloma in tertiary care Hospital, Pune
Original article Clinico hematological profile of multiple myeloma in tertiary care Hospital, Pune Dr. Sagale MS, Dr. Dangmali DP, Dr. Rane SR, Dr. Kulkarni KK, Dr. Puranik SC Department of Pathology,
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35
Myeloma: diagnosis and management NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationMeasurement of free light chains with assays based on monoclonal antibodies Te Velthuis, Henk; Drayson, Mark; Campbell, John
Measurement of free light chains with assays based on monoclonal antibodies Te Velthuis, Henk; Drayson, Mark; Campbell, John DOI:.55/cclm-25-963 License: None: All rights reserved Document Version Peer
More informationDiagnosis and staging
Chapter 2 Diagnosis and staging Carlos Fernández de Larrea and Joan Bladé Diagnostic criteria Multiple myeloma (MM) is a plasma cell disorder characterized by a clonal proliferation of cells producing
More informationTo learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation
ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION Shortly after being diagnosed with multiple myeloma, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF in 1998
More informationInformation and resources for African Americans living with multiple myeloma and their caregivers
For African Americans living with Multiple Myeloma Information and resources for African Americans living with multiple myeloma and their caregivers Standing in the Gaap: An initiative created to help
More informationPrevalence of Monoclonal Gammopathy of Undetermined Significance
The new england journal of medicine original article Prevalence of Monoclonal Gammopathy of Undetermined Significance Robert A. Kyle, M.D., Terry M. Therneau, Ph.D., S. Vincent Rajkumar, M.D., Dirk R.
More informationMyeloma Primary Care. Dr R Lovell Feb 2015
Myeloma Primary Care Dr R Lovell Feb 2015 Aims Balance of pathophysiology and cases Explain diagnostic changes (minimal) Staging UK influence Autologous stem cell transplants Primary care myeloma problems
More informationTreatment options in Myeloma. BritModis myeloma for the elderly care specialist
Treatment options in Myeloma myeloma for the elderly care specialist Dr Richard Soutar, Consultant in Haematology and Transfusion Medicine, Beatson Oncology Centre, Glasgow and The Scottish National Blood
More informationYour Test Results. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding Your Test Results u-ytr_en_2017_h4 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)
More informationMyeloma An Introduction. Myeloma Infoguide Series. Essentials
Myeloma An Introduction Myeloma Infoguide Series Essentials This publication has been made possible thanks to the generosity of Myeloma UK supporters. To find out how you can support our vital work call
More informationJournal of Immunological Methods
Journal of Immunological Methods 391 (2013) 1 13 Contents lists available at SciVerse ScienceDirect Journal of Immunological Methods journal homepage: www.elsevier.com/locate/jim Research paper Development
More informationA Study of Serum Protein Electrophoresis in Patients with Multiple Myeloma
MULTIPLE THE IRAQI POSTGRADUATE MYELOMA MEDICAL JOURNAL A Study of Serum Protein Electrophoresis in Patients with Multiple Myeloma Hind Shakir Ahmed ABSTRACT: BACKGROUND: Multiple myeloma (MM) is caused
More informationMyeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation
Myeloma Bone Disease Current and Future Treatment A Publication of The Bone and Cancer Foundation What Is Multiple Myeloma? Multiple Myeloma is a cancer that results from a malignant change in a particular
More informationPolyclonal versus monoclonal immunoglobulin-free light chains quantification
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(3) 327 336! The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563214553808 acb.sagepub.com
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
More informationDr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationDenosumab for the prevention of skeletal related events in patients with multiple myeloma first line
NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY
More informationMyeloma Expert Information About Diagnosis and Treatment
Slide 1: Myeloma Expert Information About Diagnosis and Treatment OPERATOR: Hello, everyone, and welcome to Myeloma Expert Information About Diagnosis and Treatment. It is my pleasure to introduce your
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationMultiple Myeloma: Treatment Options for Newly Diagnosed Patients in Bangladesh Perspective
Multiple Myeloma: Treatment Options for Newly Diagnosed Patients in Bangladesh Perspective *Rahman MM, 1 Aziz MA, 2 Islam MM, 3 Zaman AM, 4 Afrose S, 5 Khan MA 6 Treatment of multiple myeloma, a plasma
More informationUnderstanding Your Blood and Blood Tests
Myeloma Canada InfoGuide Series Understanding Your Blood and Blood Tests www.myeloma.ca Introduction This InfoGuide is for people living with myeloma, their families and their caregivers. It will help
More informationTreatment of Multiple Myeloma with Stem Cell Transplantation (SCT)
Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT) Görgün Akpek, MD, MHS Director, SCT and Cellular Therapy Program Banner MD Anderson Cancer Center GAkpek@mdanderson.org MULTIPLE MYELOMA
More informationCytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels
Published Ahead of Print on February 1, 2018, as doi:10.3324/haematol.2017.184226. Copyright 2018 Ferrata Storti Foundation. Cytogenetic aberrations in multiple myeloma are associated with shifts in serum
More informationGuidelines for the diagnosis and management of Myeloma within AngCN
Guidelines for the diagnosis and management of Myeloma within AngCN Ref: AngCN-SSG-Ha5 Cancer Standards Measure: N/A Page 1 of 11 Approved and Published: March 2013 1 Introduction These brief guidelines
More informationThis talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse
This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is
More informationDARATUMUMAB HARD TO PRONOUNCE - EVEN HARDER ON BLOOD BANK TESTING. Dr. Jennifer Duncan Hematopathology Resident March 18, 2017
DARATUMUMAB HARD TO PRONOUNCE - EVEN HARDER ON BLOOD BANK TESTING Dr. Jennifer Duncan Hematopathology Resident March 18, 2017 Goals and Objectives: Briefly describe the use of dara in the treatment of
More informationIntroduction. Point. Keywords: electrophoresis; Hevylite; IgA; immunoglobulin; monoclonal protein.
Clin Chem Lab Med 2015; aop Point Josie A.R. Evans*, Ellen L. Jenner, Hugh D. Carr Smith, Oscar Berlanga and Stephen J. Harding Quantification of β-region IgA monoclonal proteins shouldwe include immunochemical
More informationEvaluation of Sebia s Capillarys 2 flex-piercing system in. level monoclonal protein in serum and urine of patients
Peer reviewed ORIGINAL ARTICLE Evaluation of Sebia s Capillarys 2 flex-piercing system in comparison with Hydrasys gel system, in identifying low level monoclonal protein in serum and urine of patients
More informationHot Topic. Disclosures. None
Hot Topic Multiple Myeloma Testing at Mayo Medical Laboratories HOT TOPIC / 2017 MFMER 1 Our speaker for this program is Dragan Jevremovic, MD, PhD Assistant Professor, Division of Hematopathology at Mayo
More informationSignificance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation
Original Article Significance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation Sara L. Hall, 1 Jill Tate, 2 Devinder Gill, 1,3 *Peter Mollee 1,3
More informationSerum protein electrophoresis and immunofixation by a semiautomated electrophoresis system
Clinical Chemistry 44:5 944 949 (1998) Enzymes and Protein Markers Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system Xavier Bossuyt, * Ann Bogaerts, Gilberte Schiettekatte,
More informationAccuracy of Serum IgM and IgA Monoclonal Protein Measurements by Densitometry
160 Annals of Clinical & Laboratory Science, vol. 33, no. 2, 2003 Accuracy of Serum IgM and IgA Monoclonal Protein Measurements by Densitometry C. Howard Tseng, 1 Chin-Yung Chang, 2 Kevin S. Liu, 3 and
More informationSingle Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells
Hematopathology / Flow Cytometric Analysis of Clonal Plasma Cells Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells Derek K. Marsee,
More informationCOMBINATION THERAPY WITH LENALIDOMIDE PLUS DEXAMETHASONE (REV/DEX) FOR NEWLY DIAGNOSED MYELOMA
Blood First Edition Paper, prepublished online August 23, 2005; DOI 10.1182/blood-2005-07-2817 COMBINATION THERAPY WITH LENALIDOMIDE PLUS DEXAMETHASONE (REV/DEX) FOR NEWLY DIAGNOSED MYELOMA S. Vincent
More informationClinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationDiagnosis of Multiple Myeloma from a Blood Sample Failed To Be Centrifuged: A Case Report
Diagnosis of Multiple Myeloma from a Blood Sample Failed To Be Centrifuged: A Case Report Limin Zhang 1, Hong Lv 1, Kelin Chen 1, Fang Fang 2, Ruimin Ma 1, Guanghui Zheng 1, Jingzheng Liu 1, Chunqing Shao
More informationA Caregiver s Guide to Helping Myeloma Patients. Webinar 1, February 23, 2017 The New Normal for Caregivers of Patients With Multiple Myeloma
A Caregiver s Guide to Helping Myeloma Patients The New Normal for Caregivers of Patients With Multiple Myeloma Speakers Moderator: Mary DeRome Multiple Myeloma Research Foundation Norwalk, Connecticut
More informationTHE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org
THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters
More informationAssays and Strategies for Immunogenicity Assessment. Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen
Assays and Strategies for Immunogenicity Assessment Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen General Antibody Assay Strategy Correlation of clinical findings
More information+ Serum Protein Electrophoresis with Immunofixation
+ Serum Protein Electrophoresis with Immunofixation Dr.Ajay Phadke Centre Head SRL Diagnostics-Dr.Avinash Phadke s Lab + What is electrophoresis? Electrophoresis is a method of separating proteins based
More informationPerformance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins
Immunopathology / SEBIA CAPILLARYS 2 PARAPROTEIN DETECTION Performance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins Zhaohai Yang, MD, PhD, Keith Harrison, MD,
More informationSerum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio
Elmer ress Original Article J Clin Med Res. 2017;9(1):46-57 Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio Gurmukh
More informationMyeloma. Anne Grace, myeloma survivor. Support for this publication provided by
Myeloma Anne Grace, myeloma survivor Support for this publication provided by Revised 2017 Publication Update Myeloma The Leukemia & Lymphoma Society wants you to have the most up-to-date information about
More informationBrian GM Durie. Black Swan Research Initiative (BSRI) Purpose
Black Swan Research Initiative Brian GM Durie Saturday August 22, 2015 1 Black Swan Research Initiative (BSRI) Purpose The Black Swan Research Initiative (BSRI) is a global collaborative approach Which
More informationMyeloma Update on Treatment and Side Effects Management November 7, 2013 Speaker: Asher A. Chanan-Khan, MD
Slide 1 Welcome & Introductions OPERATOR: Hello, everyone, welcome to Myeloma Update on Treatment and, a free telephone-web education program. It is my pleasure to introduce your moderator, Lauren Berger,
More informationOperator Greetings, and welcome to the Living With Myeloma: Managing Side Effects and Quality of Life telephone and Web education program.
WELCOME AND INTRODUCTION Operator Greetings, and welcome to the Living With Myeloma: telephone and Web education program. It is now my pleasure to introduce your moderator,. Thank you, Ms. Figueroa-Rivera.
More informationMyeloma. Your Essential Guide
Myeloma Your Essential Guide Contents 3 Introduction 4 What is myeloma 7 Types of myeloma 9 What causes myeloma? 10 Diagnosis, tests, investigations and staging 14 Treatment of myeloma 19 Initial treatment
More informationPreview of the Medifocus Guidebook on: Multiple Myeloma Updated February 23, 2018
Preview of the Medifocus Guidebook on: Multiple Myeloma Updated February 23, 2018 This document is only a SHORT PREVIEW of the Medifocus Guidebook on Multiple Myeloma. It is intended primarily to give
More informationThe Myeloma Guide Information for Patients and Caregivers
The Myeloma Guide Information for Patients and Caregivers Manuel, myeloma survivor This publication was supported in part by a grant from Revised 2013 A Message From John Walter President and CEO of The
More informationCyfra 21-1 IRMA. Product information Information about other products is available at: Userś Manual DE52100
Product information Information about other products is available at: www.demeditec.com Userś Manual Cyfra 21-1 IRMA The CYFRA 21.1 IRMA system provides a direct in vitro quantitative determination of
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512 Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Monique
More informationFour Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014
Patient Power Knowledge. Confidence. Hope. Toward a Cure for Multiple Myeloma: Four Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014 Gareth Morgan,
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Prof Gordon Cook Professor of Haematology and Myeloma Studies University of Leeds & Leeds Cancer Centre #MyelomaInfodays This talk will cover The
More informationPatient Case and Question
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida
More informationHUMAN IMMUNOGLOBULIN FREE LIGHT CHAINS κ AND λ ELISA. Product Data Sheet. Cat. No.: RD R. For Research Use Only
HUMAN IMMUNOGLOBULIN FREE LIGHT CHAINS κ AND λ ELISA Product Data Sheet Cat. No.: RD194088100R For Research Use Only Page 1 of 36 VERSION 98 110511 18 CONTENTS 1. INTENDED USE 3 2. STORAGE, EXPIRATION
More informationImmunotherapy in myeloma
Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to
More informationMaxillary pain is the first indication of the presence of multiple myeloma: A case report
MOLECULAR AND CLINICAL ONCOLOGY 2: 59-64, 2014 Maxillary pain is the first indication of the presence of multiple myeloma: A case report XIAO JIAO ZHAO 1*, JIAN SUN 2*, YING DENG WANG 1 and LI WANG 1 Divisions
More information7/6/2017. Learning Objectives
Learning Objectives Monoclonal Antibody Therapeutics Potential Interferents on Protein Electrophoresis and Related Tests Maria Alice V. Willrich, Ph.D., DABCC At the end of the presentation, participants
More informationSummary. Original Article. Postepy Hig Med Dosw (online), 2017; 71: e-issn
Postepy Hig Med Dosw (online), 2017; 71: 40-46 e-issn 1732-2693 www.phmd.pl Original Article Received: 2016.03.19 Accepted: 2016.08.19 Published: 2017.01.22 DOI: 10.5604/17322693.1229346 Authors Contribution:
More informationClinical Policy: Eculizumab (Soliris) Reference Number: ERX.SPMN.225
Clinical Policy: (Soliris) Reference Number: ERX.SPMN.225 Effective Date: 01/17 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationDTT Treated Reagent Red Cells for use in Resolving DARA Interference. More Than Just Kell?? Marilyn Stewart MT(ASCP)SBB
DTT Treated Reagent Red Cells for use in Resolving DARA Interference More Than Just Kell?? Marilyn Stewart MT(ASCP)SBB Daratumumab Anti-myeloma and anti-lymphoma agent known to interfere with routine Blood
More informationClinical Trials in Multiple Myeloma in Arizona: Past, Present and Future
Clinical Trials in Multiple Myeloma in Arizona: Past, Present and Future AZMN Roundtable March 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC, FACP Staff
More informationMonitoring Multiple Myeloma
Monitoring Multiple Myeloma Kyle A. Udd, BS, Tanya M. Spektor, PhD, and James R. Berenson, MD Mr Udd is a medical research data analyst at the Institute for Myeloma & Bone Cancer Research in West Hollywood,
More informationLeukemia (2013) 27, & 2013 Macmillan Publishers Limited All rights reserved /13
Leukemia (2013) 27, 213 219 & 2013 Macmillan Publishers Limited All rights reserved 0887-6924/13 www.nature.com/leu ORIGINAL ARTICLE Immunoglobulin heavy/light chain ratios improve paraprotein detection
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_plasma_cell_dyscrasias_multiple_myeloma
More informationBN II The power of choice
BN II The power of choice BN II The intelligent system for The BN II, with more than 1500 instruments sold so far, is one of the latest additions to the successful range of BN systems. This third generation
More informationBCH 462. Single Radial Immunodiffusion and Immuno-electrophoresis
BCH 462 Single Radial Immunodiffusion and Immuno-electrophoresis Immunoassays tests include: 1. Precipitation. 2. Agglutination. 3. Immunofluorescence. 4. Radioimmunoassay (RIA). 5. Enzyme-Linked Immuno
More information